Diagnosing the decline in pharmaceutical R&D efficiency

@article{Scannell2012DiagnosingTD,
  title={Diagnosing the decline in pharmaceutical R\&D efficiency},
  author={Jack W. Scannell and Alex Blanckley and Helen Boldon and Brian Warrington},
  journal={Nature Reviews Drug Discovery},
  year={2012},
  volume={11},
  pages={191-200}
}
The past 60 years have seen huge advances in many of the scientific, technological and managerial factors that should tend to raise the efficiency of commercial drug research and development (R&D). Yet the number of new drugs approved per billion US dollars spent on R&D has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms. There have been many proposed solutions to the problem of declining R&D efficiency. However, their apparent lack of impact so far… Expand
When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis
TLDR
It is hypothesized that the average predictive validity of the stock of academically and industrially "interesting" screening and disease models has declined over time, with even small falls able to offset large gains in scientific knowledge and brute-force efficiency. Expand
The endless frontier? The recent increase of R&D productivity in pharmaceuticals
TLDR
A new set of analyses for the last decade of R&D productivity within the pharmaceutical research and development industry shows that biotechnology companies have reached levels of productivity in project development that are equivalent to those of large pharmaceutical companies. Expand
The R&D Cost of a New Medicine
The cost of R&D for a successful new medicine has been an important policy issue at least since the 1960s. Cost estimates matter not just because of intellectual curiosity or for industryExpand
The Endless Frontier? The Recent Upsurge of R&D Productivity in Pharmaceuticals
TLDR
It is shown that the observed increased performance in clinical trials is mostly due to the contribution of biotech-nological companies, while pharmaceutical companies have significantly improved their performances in identifying false positives in preclinical research. Expand
Changing R&D models in research-based pharmaceutical companies
TLDR
Research-based pharmaceutical companies need to be aware of the key factors, which impact the rate of innovation, R&D cost and probability of success, as they challenge the model of an innovation-driven pharmaceutical industry. Expand
Can adaptive clinical trials help to solve the productivity crisis of the pharmaceutical industry? - a scenario analysis
TLDR
An adaptive trial design with the potential to increase success rates of clinical trials by 4 percentage points could lower development costs for a new drug from 2.6 to 2.2bn USD, which would free up an additional 4.2 billion USD for investment into pharmaceutical R&D to bring about drug innovations. Expand
Drug discovery goes back to school: changing ecosystem of drug discovery and the rising role of academia
  • B. Slusher
  • Political Science, Medicine
  • Journal of the peripheral nervous system : JPNS
  • 2014
TLDR
As the pharmaceutical industry has been reducing its efforts in early drug discovery, there has been a simultaneous increase in the NIH’s involvement in drug discovery and translation science. Expand
A Ricardian-Demand Explanation for Changing Pharmaceutical R&D Productivity
This paper examines trends in the aggregate productivity of the pharmaceutical sector over the past three decades. We incorporate Ricardo’s insight about demand-driven productivity in settings ofExpand
Discontinued drugs in 2012: cardiovascular drugs
TLDR
The analysis of cardiovascular drugs dropped from clinical development in 2012 shows that the attrition is highest in Phase II trials and financial and strategic factors and lack of clinical efficacy are the principal reasons for these disappointments. Expand
1 New Trends in Drug Discovery
Productivity in drug discovery has been a prominent topic over the past years. The decline of number of new drug approvals and the parallel increase in research and development (R&D) costs have beenExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 119 REFERENCES
The productivity crisis in pharmaceutical R&D
TLDR
This study examines the decline of R&D productivity in pharmaceuticals in the past two decades and shows that this decline is associated with an increasing concentration ofR&D investments in areas in which the risk of failure is high, which correspond to unmet therapeutic needs and unexploited biological mechanisms. Expand
A New Look at the Returns and Risks to Pharmaceutical R&D
This study investigates the returns to R&D for 100 new drugs introduced into the United States during the decade of the 1970s. In contrast to prior studies, it incorporates several significantExpand
Rebuilding the R&D engine in big pharma.
  • J. Garnier
  • Business, Medicine
  • Harvard business review
  • 2008
TLDR
A cultural revolution and a broad transformation of the organization are necessary first steps to rebuilding the R&D engine, the GlaxoSmithKline CEO says. Expand
Why has R&D productivity declined in the pharmaceutical industry?
  • R. Ruffolo
  • Business, Medicine
  • Expert opinion on drug discovery
  • 2006
TLDR
Some of the areas where those who manage large R&D organisations may focus to improve R&S productivity are focused on, including cost-containment and maximum use of resources. Expand
How to improve R&D productivity: the pharmaceutical industry's grand challenge
TLDR
A detailed analysis based on comprehensive, recent, industry-wide data is presented to identify the relative contributions of each of the steps in the drug discovery and development process to overall R&D productivity and propose specific strategies that could have the most substantial impact in improving R &D productivity. Expand
RESEARCH AND DEVELOPMENT IN THE PHARMACEUTICAL INDUSTRY.
  • A. Smith
  • Business, Medicine
  • Dental student
  • 1965
TLDR
Basic facts about the drug industry's recent spending on research and development (R&D) and its output of new drugs are reviewed and the role of expected profits in private firms' decisions about investing in drug R&D is examined. Expand
Identifying R&D outliers
TLDR
An analysis identifying companies — which are term ‘outliers’ — that seem to have been more successful in counteracting the overall industry trend of declining R&D productivity is presented, and an initial assessment of possible characteristics differentiating them from their less successful peers is provided. Expand
R&D strategy in the U.S. pharmaceutical industry
Abstract The adverse economic impacts of the 1962 Kefauver-Harris Amendments to the Food, Drug and Cosmetic Act have transformed the U.S. pharmaceutical industry. The key elements of thisExpand
Lessons from 60 years of pharmaceutical innovation
  • B. Munos
  • Medicine
  • Nature Reviews Drug Discovery
  • 2009
TLDR
Analysis of the record of pharmaceutical innovation by analysing data on the companies that introduced the ∼1,200 new drugs that have been approved by the FDA since 1950 shows that the new-drug output from pharmaceutical companies in this period has essentially been constant, and remains so despite the attempts to increase it. Expand
A closer look at the returns and risk of pharmaceutical R&D.
TLDR
This study assesses the profitability of researching and developing new chemical entities (NCEs) based on a survey of R&D costs and on extensive U.S. sales data, finding that after 24 years of sales some two-thirds of NCEs return no more than the bonds do. Expand
...
1
2
3
4
5
...